| My Account | Subscribe | Contact Us | Donate |
Home
- Kris Freeman Skis for Olympic Gold
- Good Insulin Injection Practices
- Etiquette for People without Diabetes
- Diabetes Technology and Intimacy
- An American in the UK: Healthcare for Type 1s
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Actos Articles
The researchers’ findings, which were presented earlier this month in New Orleans during the ADA’s 69th Scientific Sessions, may lead to the use of individuals’ distinct genetic markers to identify which drugs will work best to treat their diabetes—allowing for truly customized, individualized medicine.
ID Genetic Markers That Could Improve Effectiveness of Diabetes Therapies
Scientists have identified five genetic biomarkers that predict how well a type 2 patient will respond to the drug Actos. Their work could be the first step toward a system that would allow doctors to predetermine which drugs will best help each person with diabetes.
Actos, manufactured by Takeda Pharmaceutical Company Ltd., is a thiazolidinedione, a drug that improves insulin sensitivity while decreasing the quantity of glucose and glycated hemoglobin (hemoglobin that has glucose and other sugars bound to it) in the bloodstream.
The scientists, from the University of Southern California's Keck School of Medicine and the Translational Genomics Research Institute in Phoenix, found the five biomarkers as they were investigating why up to 40 percent of patients treated with Actos fail to respond with improvement in their insulin sensitivity.
The researchers' findings, which were presented earlier this month in New Orleans during the 69th Scientific Sessions of the American Diabetes Association, may eventually lead to the use of individuals' distinct genetic markers to identify which drugs will work best to treat their diabetes-allowing for truly customized, individualized medicine. The findings may also encourage researchers to map other genetic markers that could lead to the design of more effective diabetes drugs. Finally, the research provides a greater understanding of how thiazolidinediones work, giving deeper insights into the mechanism of insulin sensitivity.
Categories: Actos, Medications Research, Research, Type 2 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
0 comments -
Jul 3, 2009 -
Email to a Friend
Send a link to this page to your friends and colleagues.